RNA, U6atac small nuclear 25, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU6ATAC25P profile across patient tissues and cancer cell-line models. RNU6ATAC25P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RNU6ATAC25P is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, RNU6ATAC25P RNA expression shows 5,930 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CESC, BRCA, and STAD as cancer lineages where RNU6ATAC25P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU6ATAC25P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU6ATAC25P survival associations across molecular data types. RNU6ATAC25P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU6ATAC25P RNA expression–survival associations across cancer types. High RNU6ATAC25P expression shows unfavorable associations in CESC, THCA, KIRC, LUSC and SKCM, but favorable associations in OV. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for RNU6ATAC25P RNA expression.
This table summarizes RNU6ATAC25P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNU6ATAC25P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU6ATAC25P shows lower tumor expression in THCA and higher tumor expression in BRCA. The BRCA box plot shows higher RNU6ATAC25P RNA expression in tumor versus normal tissue (log2 FC = +0.076, t-test p = .003).
This table shows molecular features associated with RNU6ATAC25P in patient tissues and cancer cell lines. In patient samples, RNU6ATAC25P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
